series-b
Stage
4
Investors
About
Rigontec develops RNA-based immunotherapies designed to activate the immune system to target and destroy cancer cells.
Explore Rigontec's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.